

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of the claims in this application:

**Listing of the Claims:**

Claims 1–98. (Canceled).

99. (Currently Amended) A method of diagnosing lung,—pancreatic,—or esophageal cancer, comprising detecting expression of a tumor-associated antigen in a biological sample, wherein the tumor-associated antigen is selected from the group consisting of:

- (i) the polypeptide of SEQ ID NO: 16; and
- (ii) the polypeptide encoded by the nucleic acid of SEQ ID NO: 7,

wherein detection of the tumor-associated antigen in a biological sample isolated from a patient in an amount greater than an amount of the tumor-associated antigen in a normal biological sample indicates the presence of cancer.

100. (Previously Presented) The method of claim 99, in which the detection comprises:

- (i) contacting the biological sample with an antibody which binds specifically to the tumor-associated antigen; and
- (ii) detecting a complex formed between the antibody and the tumor-associated antigen.

101. (Canceled).

102. (Previously Presented) The method of claim 100, wherein the antibody is labeled with a detectable marker.

103. (Previously Presented) The method of claim 102, wherein the detectable marker is a radioactive marker or an enzymatic marker.

104. (Previously Presented) The method of claim 99, wherein the biological sample comprises body fluid or body tissue.

105-115. (Canceled).